RxDoctor Payments Data

Gene Kim, MD

Ophthalmology · Austin, TXNPI 1639332372

Payments from drug & device makers

$16,923in general payments, 2019–2025

Across 100 payments — averaging $169.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec Cataract Technology Inc.$6K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$5K
  • Johnson & Johnson Surgical Vision, Inc.$2K
  • Alcon$1K
  • Bausch & Lomb Americas Inc.$641
  • Rxsight Inc$561
  • plus $3K from 16 others

What the payments were for

  • Consulting fees$7,50044%
  • Speaking & faculty fees$2,40014%
  • Travel & lodging$1,1647%
  • Food & beverage$5,85935%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,923 in reported general payments places this provider in the 85th percentile of 1,355 ophthalmology providers in Texas.

See all ophthalmology providers in Texas

Medicare billing

Part B allowed, 2024
$49,567
Medicare patients
139
Services billed
448

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Loteprednol Etabonate20$7,253
Prednisolone Acetate55$3,841
Difluprednate15$2,287
MoxifloxacinMoxifloxacin Hcl52$996
Fluorometholone11$687
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha70$637

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$4,649$7,25320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,355 ophthalmology providers in Texas.

Other ophthalmology in Austin

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →